Clinical trial of rasagiline combined with pramipexole in the treatment of Parkinson's disease patients
10.13699/j.cnki.1001-6821.2024.15.005
- VernacularTitle:雷沙吉兰联合普拉克索治疗帕金森病患者的临床研究
- Author:
Shi-Hong CHENG
1
;
Qiang LIN
;
Jun-Jun ZHENG
Author Information
1. 上饶市立医院神经内科,江西上饶 334000
- Keywords:
rasagiline mesylate tablet;
pramipexole dihydrochloride tablet;
levodopa and benserazide hydrochloride tablet;
Parkinson's disease;
clinical effect;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(15):2174-2177
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of the combination of rasagiline tablets and pramipexole tablets in the treatment of patients with Parkinson's disease.Methods The Parkinson's disease patients were randomly divided into treatment and control groups.The control group received pramipexole tablets,starting at a dose of 0.375 mg per day,with subsequent increases of 0.75 mg per time every 5-7 days,reaching a final dose of 1.5 mg per day.For patients with persistent poor disease control,the frequency of administration could be adjusted to twice a day,with a maximum daily dose of ≤ 4.5 mg.The treatment group received oral rasagiline in addition to the treatment in the control group,at a dose of 1.0 mg per day,once daily(qd).Both groups of patients were treated for 6 months.The clinical efficacy,inflammatory factors,serological indicators and related scales,as well as the occurrence of adverse drug reactions were compared between the two groups.Results The control group consisted of 67 participants,and the treatment group consisted of 68 participants,with no dropouts in either group.After treatment,the total effective rates of the treatment and control groups were 88.24％(60 cases/68 cases)and 74.63％(50 cases/67 cases)with significant difference(P＜0.05).After treatment,the levels of interferon-γ in treatment and control groups were(4.38±0.74)and(5.20±1.06)mg·L-1;the levels of interleukin-1 β were(0.33±0.05)and(0.59±0.12)ng·L-1;the levels of glutathione peroxidase were(108.24±11.30)and(92.88±9.79)U·μg-1;the modified Webster symptom scores were(7.26±1.05)and(13.15±3.25)points;the levels of γ-aminobutyric acid(GABA)were(278.14±41.32)and(241.86±35.04)mmol·L-1;the levels of insulin growth factor-1(IGF-1)were(170.25±20.34)and(145.18±16.51)ng·L-1,and the differences were statistically significant(all P＜0.05).The main adverse drug reactions of 2 groups were nausea and vomiting,drowsiness and dizziness.The total incidences of adverse drug reactions in treatment and control groups were 11.76％and 8.96％without significant difference(P＞0.05).Conclusion The combination of rasagiline tablets and pramipexole tablets in the treatment of patients with Parkinson's disease has shown definite clinical efficacy.It can alleviate oxidative stress and inflammatory reactions,relieve motor symptoms,regulate the expression levels of serum GABA and IGF-1,and does not significantly increase the incidence of adverse drug reactions.
